Experts discuss common patient concerns about vaccination in pregnancy and strategies to improve uptake.
News|Articles|September 28, 2026
FAQ: How should clinicians manage histoplasmosis during pregnancy?
Author(s)Contemporary OB/GYN Staff
Fact checked by: Joshua Fitch, Senior Editor
Missed the updated IDSA histoplasmosis guideline? This easy-to-read FAQ covers what clinicians caring for pregnant patients need to know.
Advertisement
Advertisement
The Infectious Diseases Society of America (IDSA) has released the second part of its update to the clinical practice guideline on histoplasmosis in adults, children, and pregnant individuals. The newest section, posted September 16, 2026, is a consensus statement on initial antifungal treatment of severe pulmonary and disseminated histoplasmosis. It joins 2 recommendations from March 2025 on asymptomatic Histoplasma pulmonary nodules (histoplasmomas) and mild or moderate acute pulmonary histoplasmosis, and together these sections form the first 2 parts of an update to the 2007 IDSA guideline.
Related to this article
Experts discuss how obstetric and pediatric clinicians can coordinate to protect newborns.
Experts review ACOG's 2026-27 guidance and the RSV window extension for pregnant and postpartum patients.
On September 9, 2026, certolizumab pegol received FDA Breakthrough Therapy Designation for APS pregnancy; Jane E. Salmon, MD, reviews the IMPACT trial results behind it.
Garima Sharma, MD, outlines validated cardiac risk scores for antenatal screening and the postpartum transitions needed to keep high-risk patients from being lost to follow-up.
Anti-CGRP antibody exposure in early pregnancy was linked to higher spontaneous abortion risk; propranolol was not.
HPV vaccination before pregnancy was linked to lower odds of preterm birth in a Swedish study of 624,713 births.
A new 3-part Lancet series reframes pregnancy as a cardiovascular risk window.
Advertisement
Advertisement